Literature DB >> 14534328

mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.

Chang-Hyuk Kwon1, Xiaoyan Zhu, Junyuan Zhang, Suzanne J Baker.   

Abstract

The mechanisms that regulate mammalian cell size during development and homeostatic maintenance are poorly understood. The tumor suppressor Pten is required for correct maintenance of mammalian neuronal soma size. Selective inactivation of Pten in postnatal granule neurons of the cerebellum and dentate gyrus in mouse causes cell-autonomous hypertrophy as well as more complex phenotypes, including progressive macrocephaly, seizures, and premature death. To determine the contribution of mTor signaling to Pten-mediated growth regulation in the mammalian nervous system, we treated Pten conditional knockout mice with CCI-779, a specific mTor inhibitor. mTor inhibition decreased the seizure frequency and death rate in Pten mutant mice, prevented the increase in Pten-deficient neuronal soma size in young mice, and reversed neuronal soma enlargement in adult mice. mTor inhibition did not decrease the size of wild-type adult neurons. Thus, mTor is required for neuronal hypertrophy downstream of Pten deficiency, but is not required for maintenance of normal neuronal soma size. mTOR inhibitors may be useful therapeutic agents for diseases in brain resulting from PTEN deficiency such as Lhermitte-Duclos disease or glioblastoma multiforme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534328      PMCID: PMC240720          DOI: 10.1073/pnas.2132711100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.

Authors:  C Rommel; S C Bodine; B A Clarke; R Rossman; L Nunez; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

2.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

Authors:  A Suzuki; M T Yamaguchi; T Ohteki; T Sasaki; T Kaisho; Y Kimura; R Yoshida; A Wakeham; T Higuchi; M Fukumoto; T Tsubata; P S Ohashi; S Koyasu; J M Penninger; T Nakano; T W Mak
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

Review 3.  Regulation of translation initiation by FRAP/mTOR.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

Review 4.  Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.

Authors:  I U Ali; L M Schriml; M Dean
Journal:  J Natl Cancer Inst       Date:  1999-11-17       Impact factor: 13.506

5.  PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.

Authors:  D J Marsh; J B Kum; K L Lunetta; M J Bennett; R J Gorlin; S F Ahmed; J Bodurtha; C Crowe; M A Curtis; M Dasouki; T Dunn; H Feit; M T Geraghty; J M Graham; S V Hodgson; A Hunter; B R Korf; D Manchester; S Miesfeldt; V A Murday; K L Nathanson; M Parisi; B Pober; C Romano; C Eng
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

6.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Authors:  K Podsypanina; R T Lee; C Politis; I Hennessy; A Crane; J Puc; M Neshat; H Wang; L Yang; J Gibbons; P Frost; V Dreisbach; J Blenis; Z Gaciong; P Fisher; C Sawyers; L Hedrick-Ellenson; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

7.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Authors:  M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

8.  Regulation of cellular growth by the Drosophila target of rapamycin dTOR.

Authors:  H Zhang; J P Stallock; J C Ng; C Reinhard; T P Neufeld
Journal:  Genes Dev       Date:  2000-11-01       Impact factor: 11.361

9.  Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin.

Authors:  S Oldham; J Montagne; T Radimerski; G Thomas; E Hafen
Journal:  Genes Dev       Date:  2000-11-01       Impact factor: 11.361

10.  PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells.

Authors:  X Zhu; C H Kwon; P W Schlosshauer; L H Ellenson; S J Baker
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

View more
  121 in total

Review 1.  Deconvoluting mTOR biology.

Authors:  Jason D Weber; David H Gutmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

2.  Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias.

Authors:  Ksenia A Orlova; Victoria Tsai; Marianna Baybis; Gregory G Heuer; Sanjay Sisodiya; Maria Thom; Kevin Strauss; Eleonora Aronica; Phillip B Storm; Peter B Crino
Journal:  J Neuropathol Exp Neurol       Date:  2010-08       Impact factor: 3.685

3.  PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes.

Authors:  Angela R White; Durgesh Tiwari; Molly C MacLeod; Steve C Danzer; Christina Gross
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

Review 4.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

5.  Stimulation-dependent remodeling of the corticospinal tract requires reactivation of growth-promoting developmental signaling pathways.

Authors:  Neela Zareen; Shahid Dodson; Kristine Armada; Rahma Awad; Nadia Sultana; Erina Hara; Heather Alexander; John H Martin
Journal:  Exp Neurol       Date:  2018-05-02       Impact factor: 5.330

Review 6.  Genetic animal models of malformations of cortical development and epilepsy.

Authors:  Michael Wong; Steven N Roper
Journal:  J Neurosci Methods       Date:  2015-04-21       Impact factor: 2.390

7.  Surviving mossy cells enlarge and receive more excitatory synaptic input in a mouse model of temporal lobe epilepsy.

Authors:  Wei Zhang; Ajoy K Thamattoor; Christopher LeRoy; Paul S Buckmaster
Journal:  Hippocampus       Date:  2014-12-26       Impact factor: 3.899

8.  Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Authors:  Dan Ehninger; Sangyeul Han; Carrie Shilyansky; Yu Zhou; Weidong Li; David J Kwiatkowski; Vijaya Ramesh; Alcino J Silva
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

9.  mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.

Authors:  Lena H Nguyen; Travorn Mahadeo; Angélique Bordey
Journal:  J Neurosci       Date:  2019-01-30       Impact factor: 6.167

10.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.